Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Oryctolagus cuniculus | Arachidonate 15-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | arachidonate 5 lipoxygenase | Arachidonate 15-lipoxygenase | 663 aa | 676 aa | 23.2 % |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Arachidonate 15-lipoxygenase | 663 aa | 676 aa | 22.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | plasmepsin I | 0.0315 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0315 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin X | 0.0315 | 0 | 0.5 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0824 | 0.0676 | 0.5 |
Plasmodium falciparum | plasmepsin IX | 0.0315 | 0 | 0.5 |
Onchocerca volvulus | 0.0315 | 0 | 0.5 | |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2498 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin VII | 0.0315 | 0 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.2498 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0315 | 0 | 0.5 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.2498 | 0.2898 | 1 |
Toxoplasma gondii | cathepsin B | 0.0824 | 0.0676 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2498 | 0.2898 | 0.2898 |
Echinococcus granulosus | cathepsin b | 0.2498 | 0.2898 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2498 | 0.2898 | 1 |
Echinococcus granulosus | cathepsin b | 0.2498 | 0.2898 | 1 |
Echinococcus multilocularis | cathepsin b | 0.2498 | 0.2898 | 1 |
Loa Loa (eye worm) | cathepsin B | 0.0824 | 0.0676 | 0.2333 |
Plasmodium vivax | aspartyl protease, putative | 0.0315 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0315 | 0 | 0.5 |
Onchocerca volvulus | 0.0315 | 0 | 0.5 | |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0824 | 0.0676 | 0.0676 |
Giardia lamblia | Cathepsin B precursor | 0.0824 | 0.0676 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0824 | 0.0676 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2498 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin V | 0.0315 | 0 | 0.5 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0824 | 0.0676 | 1 |
Giardia lamblia | Cathepsin B precursor | 0.0824 | 0.0676 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0315 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.2498 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0315 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0315 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0315 | 0 | 0.5 |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0824 | 0.0676 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0315 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0315 | 0 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.2498 | 0.2898 | 0.2898 |
Plasmodium vivax | plasmepsin V, putative | 0.0315 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0315 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.021 uM | Inhibition of rabbit 15-lipoxygenase in presence of linoleic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 0.021 uM | Inhibition of rabbit 15-lipoxygenase in presence of linoleic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 1.1 uM | Inhibition of rabbit 15-lipoxygenase in presence of arachidonic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 1.1 uM | Inhibition of rabbit 15-lipoxygenase in presence of arachidonic acid | ChEMBL. | 17656086 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.